# Large language models in biomedicine and healthcare: applications, challenges, ethics, and the path to clinical impact

> LLMs help clinicians and researchers read, summarize, and reason across notes, images, and data. Start small, protect privacy, plug into workflows, and track time saved and errors.

- Type: AI news
- Page: https://completeaitraining.com/news/large-language-models-in-biomedicine-and-healthcare/
- Published: 2025-12-02
- Updated: 2025-12-02
- Author: Jeroen Erne
- Jobs: Healthcare
- Reading time: 4 min

### Large language models in biomedicine and healthcare: what matters now

Healthcare runs on text and signals: notes, labs, images, genomics, and the endless stream of literature. Large language models (LLMs) give us a way to read, summarize, and reason across it at speed. When used well, they cut clicks, surface insights, and help teams make better calls faster.

The catch: privacy, bias, and workflow fit. You don't need a moonshot. You need clear use cases, strong guardrails, and tight integration with clinical systems. Below is a practical guide-what LLMs do well today, where they struggle, and how to implement safely.

#### Where LLMs deliver value today

#### Genomics

- **Variant effect prediction:** Models like Enformer and GPN learn long-range genomic interactions and predict how variants influence gene expression. Useful for prioritizing variants in rare disease workups and research pipelines.
- **Cis-regulatory region mapping:** DNABERT and Nucleotide Transformer learn motifs and context to score promoters, enhancers, and splice sites-even in low-data settings.
- **DNA-protein interactions:** Self-supervised models (e.g., MoDNA, GROVER) predict transcription factor binding and regulatory elements directly from sequence.

#### Transcriptomics

- **Cell-type annotation:** scBERT, Geneformer, and scGPT transfer knowledge from millions of cells to label new datasets and expose rare states.
- **Batch effect correction:** tGPT and SCimilarity create unified embeddings that travel across studies, aiding atlas-scale queries.
- **Perturbation prediction:** scGPT forecasts gene and drug responses by modeling gene-gene interactions; promising for target discovery and hypothesis testing.
- **Spatial labels:** Nicheformer blends single-cell and spatial data to predict niches and regions, supporting tissue mapping and tumor microenvironment studies.

#### Proteomics

- **Structure prediction:** ESM-style models, MSA Transformer, and ProLLaMA push sequence-to-structure accuracy and support protein engineering workflows.
- **Function annotation:** FAPM and ProteinChat link sequences and 3D embeddings to Gene Ontology terms and catalytic activities, helpful when homologs are scarce.
- **Protein-protein interactions:** ProLLM uses a "chain of thought" strategy to reason about signaling pathways and predict interaction pairs.

#### Drug discovery

- **De novo generation:** MolFM and TGM-DLM generate valid, property-aligned molecules guided by text prompts and diffusion over SMILES tokens.
- **Drug-target interactions (DTIs):** DTI-LM and DLM-DTI improve warm- and cold-start DTI predictions with compact architectures that run on modest hardware.
- **Compound screening:** Generalist therapeutic LLMs (e.g., Tx-LLM) unify molecules, proteins, and text to triage libraries and suggest repurposing leads.

#### Biomedical informatics

- **Question answering:** Retrieval-augmented systems like BioRAG reason over millions of papers to answer clinical or research questions with citations.
- **Summarization:** BioMedLM-level models condense notes, trials, and guidelines; reader studies often prefer their summaries for completeness and clarity.
- **Clinical decision support (early signals):** Studies in precision oncology show LLMs can suggest options that complement specialist judgment-useful as a second set of eyes, not a final arbiter.

#### Implementation playbook for healthcare teams

- **Start with a narrow, high-friction task:** discharge summary drafts, prior-auth letter drafts, tumor board evidence packs, variant triage notes, or trial-matching candidate lists.
- **Keep data private:** use de-identified corpora for training; run inference in a protected environment; contractually ban secondary data use.
- **Build on RAG:** retrieve from guidelines, pathways, formularies, institutional policies, and local order sets so the model cites what your clinicians trust.
- **Wire into existing systems:** FHIR, SQL, or graph backends as tools; let the model read but not write without review. Keep audit logs.
- **Human-in-the-loop:** clinicians approve outputs; require rationale and sources; mandate uncertainty flags.
- **Measure what matters:** time saved, error rates, rework, guideline adherence, and patient outcomes. Sunset what doesn't move the needle.
- **Iterate with guardrails:** prompt templates, content filters, PHI redaction, and fallbacks when confidence is low.

#### Data governance, bias, and safety

- **Privacy by design:** de-identify training data; restrict PHI exposure; enforce least-privilege access. HIPAA obligations still apply. See [HHS HIPAA Privacy Rule](https://www.hhs.gov/hipaa/for-professionals/privacy/index.html?ref=completeaitraining.com).
- **Bias checks:** stratify metrics by sex, age, race/ethnicity, language, insurance, and site. Track drift over time and retrain with counterfactuals where feasible.
- **Transparency:** require citations, highlight uncertainty, and expose which data sources were used. Keep versioned prompts and models.
- **Regulatory awareness:** for patient-facing or device-like use, review the FDA's direction on AI/ML-enabled medical devices: [FDA guidance portal](https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices?ref=completeaitraining.com).
- **Incident response:** define pathways to report harmful outputs, misclassification, or data leakage; pause and patch quickly.

#### Technical choices that matter

- **RAG vs. fine-tuning:** RAG is safer for fast updates and institutional specificity; fine-tune when you need stable style or domain reasoning.
- **Structured data:** encode labs, meds, and vitals as prompts; or let the model call tools (FHIR Server, SQL, graph) for up-to-date values.
- **Efficiency:** use LoRA/QLoRA, 4-8 bit quantization, and domain adapters to cut compute and cost.
- **Evaluation:** blend automated metrics (factuality, citation accuracy) with expert review. For research tasks, pre-register evaluations to reduce hindsight bias.
- **Security:** isolate workloads, scrub prompts/outputs for PHI, and disable training on user data by default.

#### Known limitations (plan around these)

- **Data scarcity and bias:** rare diseases, pediatric cohorts, and underrepresented populations remain under-labeled; models mirror those gaps.
- **Interpretability:** attention maps aren't explanations. Use rationales, citations, and counterfactual tests; keep humans in control.
- **Cost:** large models strain GPU budgets. Prefer smaller domain models with retrieval; scale only if outcomes justify it.
- **Biological plausibility:** generated molecules or interactions may be synthetically impractical or physiologically off. Add constraints and expert review.
- **Multimodality:** integrating sequence, structure, expression, images, and EHR is still early. Expect brittle edges across modalities.
- **Evaluation ground truth:** biology is noisy; many "labels" are provisional. Use multiple assays or literature triangulation where possible.

#### 12-month sample roadmap

- **Q1:** pick 1-2 low-risk use cases; deploy RAG prototype; secure data agreements; define metrics.
- **Q2:** pilot with 10-30 clinicians or scientists; weekly feedback; cut prompts that confuse; add guardrails.
- **Q3:** expand to a second department; integrate with FHIR/graph tools; formalize bias and safety reviews.
- **Q4:** cost-optimizations (LoRA, quantization); external validation; publish internal guidance and training.
- **Ongoing:** monitor drift, re-evaluate models quarterly, and keep a kill switch.

#### What "good" looks like

- Clinicians save minutes per note and get better first drafts; fewer clicks in the EHR.
- Researchers prioritize variants, interactions, or compounds with higher hit rates downstream.
- Outputs include sources, uncertainty, and match institutional guidelines.
- Governance is clear: data use, auditing, escalation, and model lifecycle all documented.

#### Key model examples to know (non-exhaustive)

- **Genomics:** Enformer, GPN, DNABERT, Nucleotide Transformer, MoDNA, GROVER
- **Transcriptomics:** scBERT, Geneformer, scGPT, tGPT, SCimilarity, Nicheformer
- **Proteomics:** ESM-2, MSA Transformer, ProLLaMA, FAPM, ProteinChat, ProLLM
- **Drug discovery:** MolFM, TGM-DLM, DTI-LM, DLM-DTI, Tx-LLM
- **Biomedical NLP:** BioBERT, PubMedBERT, BioMegatron, BioMedLM, BioGPT, BioRAG

#### Further learning

Want structured, role-based training for your team? Explore practical AI courses by job category at [Complete AI Training](https://completeaitraining.com/courses-by-job/).

Bottom line: start small, keep humans in the loop, and measure outcomes that matter. The teams that win will pair solid clinical judgment with disciplined use of models and data.

---

This is the Markdown form of https://completeaitraining.com/news/large-language-models-in-biomedicine-and-healthcare/. The whole site is mapped at https://completeaitraining.com/llms.txt.
